Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05964829

Impact of the Cionic Neural Sleeve on Mobility in Multiple Sclerosis

The purpose of this research is to support the clinical value of the Cionic Neural Sleeve for individuals diagnosed with multiple sclerosis (MS).

Recruiting

Interested in participating?

Request Info

Key information

Age range

22 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Cleveland State University

Cleveland, Ohio, 44115, United States

Location status: Recruiting

Location contact

Douglas A Wajda

CONTACT

About this study

The randomized within-participants crossover 12-week study aims to demonstrate the clinical impact of the Cionic Neural Sleeve for individuals diagnosed with MS.

Physical measurements, performance-based tests, and questionnaire responses will be recorded. These include physical activity recorded by the Cionic Neural Sleeve; in-person tests measuring disability, spasticity and balance; and questionnaires gauging perceived walking ability, quality of life, and physical and psychological impact of MS.

All participants will be assigned a Cionic Neural Sleeve on the most impacted leg for 6 weeks, and prescribed a home-based intervention of 15 minutes of walking for 5 days a week for 12 weeks. The Cionic Neural Sleeve will be worn for 6 weeks of the study while following the walking program.

Participants will be randomized to one of two groups: A or B. Group A will follow the walking program and wear the Neural Sleeve to receive stimulation assisted walking from the Neural Sleeve for 6 weeks. Group B will follow the walking program for 6 weeks. After 6 weeks, participants in each group will cross over to the other group.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Persons with relapsing-remitting or progressive forms of MS between the ages of 22 and 75
  • Ability to ambulate at least 15 minutes throughout the day for five days per week, with or without assistive device
  • Adequate cognitive and communicative function as assessed via Telephone Interview for Cognitive Status (TICS) to identify persons with dementia
  • Able to tolerate the Neural Sleeve device for up to 8 hours per day
  • T25FWT time between 8 and 45 seconds
  • No recent change in medication or recent exacerbation of symptoms over the last 60 days
  • Patient-determined Disease Steps score between 3 and 5 or EDSS score between 4 and 6.5

Exclusion criteria

  • Lower motor neuron disease or injury (e.g. peripheral neuropathy) that may impair response to stimulation
  • Absent sensation in the impacted or more impacted leg
  • Inadequate response to stimulation, defined by inability to achieve muscle contraction or unable to tolerate stimulation
  • Inability to ambulate with the sleeve in place of an ankle foot orthosis (AFO)/knee ankle foot orthosis (KAFO) if utilized
  • History of falls greater than once a week
  • No use of FES devices in the past year
  • Demand-type cardiac pacemaker or defibrillator
  • Malignant tumor in the impacted or more impacted leg
  • Existing thrombosis in the impacted or more impacted leg
  • Fracture or dislocation in the impacted or more impacted leg that could be adversely affected by motion from stimulation

Treatment and study plan

Cionic Neural Sleeve NS-100

Device

The Cionic Neural Sleeve applies functional electrical stimulation as subjects walk to help contract appropriate muscles at appropriate times. The Cionic Neural Sleeve will be worn for 6 weeks.

Walking program

Behavioral

15 minutes of walking for 5 days per week for 6 weeks

Primary outcomes

  1. Change in Gait Speed

    Time frame: Day 0, Week 6, Week 12

    The Timed 25-Foot Walk Test (T25FWT) to record duration of time to walk a distance of 25 feet, measured in seconds. The score is the average of two successive trials.

  2. Change in Perceived Walking Ability

    Time frame: Day 0, Week 6, Week 12

    Multiple Sclerosis Walking Scale-12 (MSWS-12) to measure perceived impact of MS on walking ability, measured by score. Scores on the MSWS-12 range from 12-60 and transformed to a scale with a range from 0 to 100, with high scores indicative of a greater impact of MS on walking.

  3. Change in MS Disability

    Time frame: Day 0, Week 6, Week 12

    A 9-item survey, Patient-Determined Disease Steps (PDDS), will measure of disability status in individuals with MS. The PDDS ranges from 0 to 8, with higher values indicative of higher levels of disability.

  4. Amount of Daily Walking/Activity Level

    Time frame: During allocation to receive the functional electrical stimulation arm

    Collected by the usage log of the device, measured in steps per day

  5. Duration of Daily Walking/Activity Level

    Time frame: During allocation to receive the functional electrical stimulation arm

    Collected by the usage log of the device, measured in duration of activity.

Other outcomes

  1. Change in Health-Related Quality of Life

    Time frame: Day 0, Week 6, Week 12

    The Euroqol 5 Dimension 5 Level (EQ-5D-5L) questionnaire describes health profiles using different domains, measured by a 5-digit code. Single-digit numbers of the dimensions range from 1 to 5, with 1 indicative of no problem and 5 indicative of extreme problems in that domain.

  2. Change in Impact of MS

    Time frame: Day 0, Week 6, Week 12

    Multiple Sclerosis Impact Scale-29 (MSIS-29) questionnaire to measure the physical and psychological impact of MS, measured by score. Scores on the MSIS-29 are transformed into a score out of 100, with higher scores indicative of greater degree of disability.

  3. Change in Perceived Fatigue

    Time frame: Day 0, Week 6, Week 12

    Modified Fatigue Impact Scale (MFIS) survey to measure the effects of fatigue in physical, cognitive, and psychosocial functioning. MFIS score ranges from 0 to 84, with high scores indicative of a greater impact of fatigue on activities.

  4. Change in Spasticity

    Time frame: Day 0, Week 6, Week 12

    A trained clinician will administer the Modified Ashworth Scale (MAS) to assess for muscle tone and spasticity. Scores of the MAS range from 0 to 4, with high scores representative of increased muscle tone and spasticity.

  5. Change in Lower Limb Strength

    Time frame: Day 0, Week 6, Week 12

    Strength assessment of the ankle dorsiflexors, hamstrings, and quadriceps muscles using a handheld dynamometer in seated or laying in prone, measured in Newtons.

  6. Change in Ankle Plantarflexor Strength

    Time frame: Day 0, Week 6, Week 12

    Ankle plantarflexor strength will be measured by maximal repetitions of single leg heel raises.

  7. Change in Lower Limb Range of Motion

    Time frame: Day 0, Week 6, Week 12

    Range of motion of the ankle, knee, and hips will be assessed by a trained clinician using a handheld goniometer.

  8. Change in Walking Endurance

    Time frame: Day 0, Week 6, Week 12

    Measured via the 6-minute walk test, where subjects will walk as far as possible for 6 minutes, measured in meters.

  9. Change in Balance

    Time frame: Day 0, Week 6, Week 12

    Measured using force platform posturography in standing to quantify postural sway. There will be four 30-second trials with eyes open standing as still as possible.

  10. Change in Incidence of Falls

    Time frame: From enrollment to end of treatment at 12 weeks

    Measured using a self-reported fall diary and a survey, the Hopkins Fall Grading Scale, a 4-point scale to grade the nature and severity of a fall. Higher grades represent increased severity and impact of injurious falls.

  11. Change in Medication(s) and Dosage

    Time frame: Day 0, Week 6, Week 12

    Measured by changes in dose intensities of prescribed medication(s).

  12. Change in Pain

    Time frame: Day 0, Week 6, Week 12

    Measured using the questionnaire, the Numeric Pain Rating Scale (NPRS), an 11-point numeric scale ranging from 0 to 10, with 0 being no pain and 10 being worst pain imaginable.

  13. Change in Self-Reported Physical Activity

    Time frame: From enrollment to end of treatment at 12 weeks

    Subjects will record their weekly physical activity using the Godin-Leisure Time Exercise Questionnaire (GLTEQ), measured by score. Scores less than 14 units are interpreted as insufficiently active/sedentary, while scores between 14 and 23 are interpreted as moderately active, and scores greater than 24 units are interpreted as active.

Study contacts

Contact information is provided by the study sponsor or research team.

Douglas A Wajda, PhD

CONTACT

[email protected]

3308837149

Rebecca Webster, PhD

CONTACT

[email protected]

925-788-6649

Sponsors and collaborators

Lead sponsor

Cionic, Inc.

Industry

Registry information

Official study title

A Crossover Study Evaluating the Impact of the Cionic Neural Sleeve on Mobility, Disability, Fall Risk, and Physical Activity in Multiple Sclerosis

Important dates

Study start
2023
Primary completion
2026
Study completion
2026
First posted
Jul 28, 2023
Registry last updated
Sep 24, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.